Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation

American Journal of Clinical Nutrition

Volumn 91, Issue 6, 2010, Pages 1590-1597

  Kennedy, David O ^a   Wightman, Emma L ^a   Reay, Jonathon L ^a   Lietz, Georg ^b   Okello, Edward J ^b   Wilde, Anthea ^a   Haskell, Crystal F ^a  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYHEMOGLOBIN; DRUG METABOLITE; PLACEBO; RESVERATROL; RESVERATROL GLUCURONIDE; RESVERATROL SULFATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; FATIGUE; FEMALE; FRONTAL CORTEX; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEAR INFRARED SPECTROSCOPY; NORMAL HUMAN; OXYGEN CONSUMPTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TASK PERFORMANCE;

ADOLESCENT; ADULT; CEREBROVASCULAR CIRCULATION; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRONTAL LOBE; HEMOGLOBINS; HUMANS; MALE; SPECTROSCOPY, NEAR-INFRARED; STILBENES; VASODILATOR AGENTS; YOUNG ADULT;

EID: 77953032816     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.2009.28641     Document Type: Article

References (58)

1. Chung I-M, Park MR, Chun JC, Yun SJ. Resveratrol accumulation and resveratrol synthase gene expression in response to abiotic stresses and hormones in peanut plants. Plant Sci 2003;164:103-109
2. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008;658:68-94.
3. Rocha-Gonzalez HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther 2008;14:234-247
4. Fan E, Zhang LJ, Jiang S, Bai YH. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008;11:610-614
5. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113.
6. Joseph JA, Fisher DR, Cheng V, Rimando AM, Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J Agric Food Chem 2008;56: 10544-10551
7. Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol 2008;600:78-82.
8. Kumar P, Padi SSV, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol 2006;17:485-492 (Pubitemid 44325810)
9. Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 2002;71:2489-2498
10. Sonmez U, Sonmez A, Erbil G, Tekmen I, Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 2007;420:133-137
11. Li Y, Cao ZX, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res 2006;53:6-15.
12. Robb EL, Winkelmolen L, Visanji N, Brotchie J, Stuart JA. Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochem Biophys Res Commun 2008;372:254-259
13. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol 2008;591:66-72.
14. Chander V, Chopra K. Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res 2006; 37:19-26. (Pubitemid 41727886)
15. Shen MY, Hsiao G, Liu CL, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 2007;139:475-485
16. Gresele P, Pignatelli P, Guglielmini G, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 2008;138:1602-1608
17. Chen CK. PaceAsciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996;27:363-366
18. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009;77:'053-63.
19. Rush JW, Quadrilatero J, Levy AS, Ford RJ. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med (Maywood) 2007;232:814-822
20. Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002;106:1652-1658
21. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, Huang YZ. Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med 2001;8:3-17.
22. Chan SL, Capdeville-Atkinson C, Atkinson J. Red wine polyphenols improve endothelium-dependent dilation in rat cerebral arterioles. J Cardiovasc Pharmacol 2008;51:553-558
23. Ritz MF, Curin Y, Mendelowitsch A, Andriantsitohaina R. Acute treatment with red wine polyphenols protects from ischemia-induced excitotoxicity, energy failure and oxidative stress in rats. Brain Res 2008;1239:226-234
24. Ritz MF, Ratajczak P, Curin Y, et al. Chronic treatment with red wine polyphenol compounds mediates neuroprotection in a rat model of ischemic cerebral stroke. J Nutr 2008;138:519-525
25. Tsai SK, Hung LM, Fu YT, et al. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J Vasc Surg 2007;46:346-353
26. Gally JA, Montague PR, Reeke GN, Edelman GM. The no hypothesis - possible effects of a short-lived, rapidly diffusible signal in the development and function of the nervous-system. Proc Natl Acad Sci USA 1990;87:3547-3551
27. Kitaura H, Uozumi N, Tohmi M, et al. Roles of nitric oxide as a vasodilator in neurovascular coupling of mouse somatosensory cortex. Neurosci Res 2007;59:160-171 (Pubitemid 47429772)
28. Buerk DG, Ances BM, Greenberg JH, Detre JA. Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. Neuroimage 2003;18:1-9.
29. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32:1377-1382 (Pubitemid 39564557)
30. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009;53:S7-15.
31. Wenzel E, Somoza V. Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res 2005;49:472-481
32. Boocock DJ, Faust GES, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-1252
33. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506.
34. Juan ME, Maijó M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 2010;51:391-398
35. Steinbrink J, Villringer A, Kempf F, Haux D, Boden S, Obrig H. Illuminating the BOLD signal: combined fMRI-fNIRS studies. Magnetic Res Imaging 2006;24:495-505.
36. Huppert TJ, Hoge RD, Diamond SG, Franceschini MA, Boas DA. A temporal comparison of BOLD, ASL, and NIRS hemodynamic responses to motor stimuli in adult humans. Neuroimage 2006;29:368-382
37. Ye JC, Tak S, Jang KE, Jung J, Jang J. NIRS-SPM: statistical parametric mapping for near-infrared spectroscopy. Neuroimage 2009;44:428-447
38. Schecklmann M, Ehlis AC, Plichta MM, Fallgatter AJ. Functional near-infrared spectroscopy: a long-term reliable tool for measuring brain activity during verbal fluency. Neuroimage 2008;43:147-155
39. Schecklmann M, Ehlis A-C, Plichta MM, Boutter HK, Metzger FG, Fallgatter AJ. Altered frontal brain oxygenation in detoxified alcohol dependent patients with unaffected verbal fluency performance. Psychiatry Res Neuroimaging 2007;156:129-138
40. Kanamaru Y, Kikukawa A, Miyamoto Y, Hirafuji M. Dimenhydrinate effect on cerebral oxygen status and salivary chromogranin-A during cognitive tasks. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 107-115
41. Bönöczk P, Panczel G, Nagy Z. Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study. Eur J Ultrasound 2002;15:85-91. (Pubitemid 34578573)
42. Obrig H, Villringer A. Beyond the visible-imaging the human brain with light. J Cereb Blood Flow Metab 2003;23:1-18. (Pubitemid 36015089)
43. Drummond SP, Brown GG, Stricker JL, Buxton RB, Wong EC, Gillin JC. Sleep deprivation-induced reduction in cortical functional response to serial subtraction. Neuroreport 1999;10:3745-3748
44. Lawrence NS, Ross TJ, Stein EA. Cognitive mechanisms of nicotine on visual attention. Neuron 2002;36:539-548
45. Kennedy DO, Haskell CF, Robertson B, et al. Improved cognitive performance and mental fatigue following a multi-vitamin and mineral supplement with added guarana (Paullinia cupana). Appetite 2008;50: 506-513
46. Kennedy DO, Scholey AB. A glucose-caffeine 'energy drink' ameliorates subjective and performance deficits during prolonged cognitive demand. Appetite 2004;42:331-333
47. Reay JL, Kennedy DO, Scholey AB. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity. J Psychopharmacol 2005;19:357-365
48. Reay JL, Kennedy DO, Scholey AB. Effects of Panax ginseng, consumed with and without glucose, on blood glucose levels and cognitive performance during sustained 'mentally demanding' tasks. J Psychopharmacol 2006;20:771-781
49. Scholey AB, Harper S, Kennedy DO. Cognitive demand and blood glucose. Physiol Behav 2001;73:585-592
50. Hoshi Y. Functional near-infrared spectroscopy: current status and future prospects. J Biomed Opt 2007;12:062106.
51. Kepple G. Design and analysis. Upper Saddle River, NJ: Prentice Hall, 1991.
52. Szilágyi G, Nagy Z, Balkay L, et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 2005;229-230:275-284
53. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342
54. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006;127:1109-1122
55. Murase T, Haramizu S, Ota N, Hase T. Suppression of the aging-ssociated decline in physical performance by a combination of resveratrol intake and habitual exercise in senescence-accelerated mice. Biogerontology 2009;10:423-434
56. Abd El-Mohsen M, Bayele H, Kuhnle G, et al. Distribution of [3H] trans-resveratrol in rat tissues following oral administration. Br J Nutr 2006;96:62-70.
57. Kamper AM, Spilt A, de Craen AJM, van Buchem MA, Westendorp RGJ, Blauw GJ. Basal cerebral blood flow is dependent on the nitric oxide pathway in elderly but not in young healthy men. Exp Gerontol 2004;39:1245-1248
58. Farkas E, de Wilde MC, Kiliaan AJ, Luiten PGM. Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: window of treatment. Drugs Today (Barc) 2002;38:365-376